A 6

Drug Profile

A 6

Alternative Names: Angstrom 6; Å6

Latest Information Update: 18 Jul 2016

Price : $50

At a glance

  • Originator Angstrom Pharmaceuticals
  • Class Antineoplastics; Eye disorder therapies; Peptides
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; CD44 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Age-related macular degeneration; Diabetic retinopathy

Most Recent Events

  • 11 Jul 2016 Angstrom Pharmaceuticals terminates a phase II trial in Chronic lymphocytic leukaemia (First-line therapy) in USA (NCT02046928)
  • 27 Jul 2015 Phase-II development is ongoing for Ovarian cancer in USA
  • 19 Feb 2014 Preclinical development is ongoing in Age-related macular degeneration & Diabetic retinopathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top